Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00547521 · ClinicalTrials.gov registry record · Phase 3

Phase IIIB Subcutaneous Abatacept Monotherapy Study

A Phase 3 study of Rheumatoid Arthritis (RA), sponsored by Bristol-Myers Squibb.

Completed
Registry status
Phase 3
Development phase
119
Enrollment target
20
Study locations

NCT00547521 is a Phase 3 study of Rheumatoid Arthritis (RA) that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 119 participants, below the 261-participant average among 17 other Rheumatoid Arthritis (RA) trials with a reported enrollment target (54% lower). The trial reports 20 study locations across 17 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00547521, a Phase 3 study of Rheumatoid Arthritis (RA), has completed, sponsored by Bristol-Myers Squibb.

COMPLETED
Registry status
Phase 3
Development phase
119 participants
Enrollment target
20
Study locations

Study Summary

To evaluate safety and immunogenicity of abatacept when used with or without methotrexate in the absence of an IV loading dose of abatacept

Conditions Studied

Interventions

  • DRUG Methotrexate (MTX)
  • DRUG abatacept

Study Locations (20)

Alabama

  • Rheumatology Associates Of North Alabama - Huntsville
  • Coastal Clinical Research Inc - Mobile

Pennsylvania

  • East Penn Rheumatology Associates - Bethlehem
  • Altoona Center For Clinical Research - Duncansville

South Carolina

  • Low Country Rheumatology, Pa - Charleston
  • Columbia Arthritis Center - Columbia

California

  • Stanford University School Of Medicine - Palo Alto

Colorado

  • Boulder Medical Center - Boulder

Florida

  • The Arthritis Center - Palm Harbor

Kentucky

  • Medical Towers South - Louisville

Nebraska

  • Westroads Medical Group - Omaha

Trial Details

FieldValue
Enrollment Target 119 participants
Start Date 2007-12
Est. Completion 2014-02
Phase Phase 3

Sponsor

Bristol-Myers Squibb

1,025 total trials

What the Registry Record Tells You About NCT00547521

The ClinicalTrials.gov registry entry for NCT00547521 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 119 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 261-participant average among 17 other Rheumatoid Arthritis (RA) trials with a reported enrollment target (54% lower). The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Rheumatoid Arthritis (RA) appearing as the primary indexed condition, and to 2 interventions - of which Methotrexate (MTX) is the first listed.

NCT00547521 reports 20 study locations spanning 17 distinct geographic areas - top geographies include Alabama, Pennsylvania, South Carolina.

Frequently Asked Questions

What is clinical trial NCT00547521 about?

NCT00547521 is a clinical study titled "Phase IIIB Subcutaneous Abatacept Monotherapy Study". To evaluate safety and immunogenicity of abatacept when used with or without methotrexate in the absence of an IV loading dose of abatacept

What is the current status of trial NCT00547521?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 119 participants. The study started on 2007-12. Estimated completion is 2014-02.

What conditions does trial NCT00547521 study?

This clinical trial studies the following conditions: Rheumatoid Arthritis (RA).

What interventions are being tested in trial NCT00547521?

The interventions under investigation include: Methotrexate (MTX) (DRUG), abatacept (DRUG).

Who is sponsoring clinical trial NCT00547521?

This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00547521 being conducted?

This trial has 20 study locations across Alabama, California, Colorado, Florida, Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Rheumatoid Arthritis (RA)

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.